{"id":"W3032740647","doi":"10.1200/jco.2020.38.15_suppl.8500","title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Tolerability; Neutropenia; Adverse effect; Internal medicine; Dexamethasone; Multiple myeloma; Bortezomib; Febrile neutropenia; Gastroenterology; Pharmacology; Oncology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009479088,0.001473626,0.001387442,0.0003628641,0.0004091334,0.0009261068,0.0008073151,0.0008140198,0.004242369],"category_scores_gemma":[0.0005582311,0.0006545366,0.0009154908,0.0003823247,0.0008732591,0.0007409168,0.0003752175,0.002847492,0.001252935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074061,"about_ca_system_score_gemma":0.001240811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001377798,"about_ca_topic_score_gemma":0.003092074,"domain_scores_codex":[0.9996688,0.0001417767,0.00001690671,0.00006491582,0.00003044314,0.00007719817],"domain_scores_gemma":[0.9995309,0.00004997231,0.00008257906,0.00003827778,0.00002488472,0.0002733797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5249376,0.1645353,0.01540363,0.000928523,0.001639815,0.0008774319,0.0006440778,0.00386809,0.1228737,0.0003865926,0.006972312,0.1569329],"study_design_scores_gemma":[0.2446435,0.7251403,0.01391016,0.00003229657,0.0004327865,0.0006232458,0.00009356719,0.0009747521,0.008542199,0.0001269674,0.005451874,0.00002843299],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915177,0.0021959,0.0006103229,0.0003415908,0.0001020731,0.002108097,0.001078604,0.0001144397,0.001931121],"genre_scores_gemma":[0.991123,0.001525475,0.001538355,0.0005055644,0.0001577274,0.001179713,0.001713672,0.0000342293,0.00222228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004242369,"threshold_uncertainty_score":0.0141921,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05902830631515678,"score_gpt":0.363408366161987,"score_spread":0.3043800598468303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}